Literature DB >> 18083556

Inhibition of tubulin polymerization by select alkenyldiarylmethanes.

Matthew D Cullen1, Taradas Sarkar, Ernest Hamel, Tracy L Hartman, Karen M Watson, Robert W Buckheit, Christophe Pannecouque, Erik De Clercq, Mark Cushman.   

Abstract

During studies on the alkenyldiarylmethane (ADAM) class of non-nucleoside reverse transcriptase inhibitors (NNRTIs), analogues were discovered that exhibit low micromolar and submicromolar cytotoxicities. Since the ADAMs are structurally related to the tubulin polymerization inhibitor CC-5079, a set of 14 ADAMs were tested for inhibition of tubulin polymerization in an attempt to identify the biological target responsible for their cytotoxicity. The results indicate that, overall, the ADAMs are poor inhibitors of tubulin polymerization. However, the two most cytotoxic compounds, 15 and 16, are in fact active as inhibitors of tubulin assembly with IC(50) values of 3.7+/-0.3 and 2.8+/-0.2 microM, respectively, and they both inhibit the binding of colchicine to tubulin. Both compounds were investigated for anticancer activity in the National Cancer Institute's panel of 60 human cancer cell lines, and both compounds consistently displayed submicromolar cytotoxicities with mean-graph midpoint (MGM) values of 0.31+/-0.08 and 0.47+/-0.09 microM, respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083556      PMCID: PMC2255563          DOI: 10.1016/j.bmcl.2007.11.114

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

Review 1.  Tubulin-targeting agents.

Authors:  William N Hait; Eric Rubin; Susan Goodin
Journal:  Cancer Chemother Biol Response Modif       Date:  2003

2.  RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates.

Authors:  S G Kerr; K S Anderson
Journal:  Biochemistry       Date:  1997-11-18       Impact factor: 3.162

3.  Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Bo-Liang Deng; Tracy L Hartman; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Phillip E Fanwick; Mark Cushman
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

4.  The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.

Authors:  Ling-Hua Zhang; Lei Wu; Heather K Raymon; Roger S Chen; Laura Corral; Michael A Shirley; Rama Krishna Narla; Jim Gamez; George W Muller; David I Stirling; J Blake Bartlett; Peter H Schafer; Faribourz Payvandi
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.

Authors:  M Cushman; W M Golebiewski; L Graham; J A Turpin; W G Rice; V Fliakas-Boltz; R W Buckheit
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

6.  Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.

Authors:  Takeshi Sakamoto; Matthew D Cullen; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Journal:  J Med Chem       Date:  2007-06-19       Impact factor: 7.446

7.  Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles.

Authors:  E Hamel; C M Lin
Journal:  Biochemistry       Date:  1984-08-28       Impact factor: 3.162

8.  Mechanism and fidelity of HIV reverse transcriptase.

Authors:  W M Kati; K A Johnson; L F Jerva; K S Anderson
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

Review 9.  Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals.

Authors:  W G Rice; J P Bader
Journal:  Adv Pharmacol       Date:  1995

10.  HIV-1 Tat, apoptosis and the mitochondria: a tubulin link?

Authors:  Mauro Giacca
Journal:  Retrovirology       Date:  2005-02-07       Impact factor: 4.602

View more
  2 in total

Review 1.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

Review 2.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.